Climb Bio is excited to attend the Leerink Healthcare Therapeutics Forum. We're looking forward to engaging with fellow innovators and investors and discussing the future of immunology. Let’s connect! $CLYM #ClimbHigher #Leerink #InvestorConference

Climb Bio is attending the BTIG Virtual Biotechnology Forum. Looking forward to connecting with healthcare innovators. $CLYM #HealthcareInnovation #BTIGBiotech

#ICYMI Dosed patients in budoprutug ITP & SLE trials Expect to initiate Ph2 pMN and Ph1 SC formulation trials soon Anti-APRIL antibody CLYM116 on track to submit IND or CTA in IgA nephropathy in H2 2025 Details to come on September investor event 🔗 loom.ly/34FrNk0

CLYM116 Advancing Toward Clinical Development Innovation is core to Climb’s #YearOfExecution. Through our exclusive license with Mabworks, CLYM116 remains on track to submit an IND or CTA in IgAN in H2 2025. Don’t miss our investor event—preclinical data coming in September.

#ICYMI: Climb Bio kicks off September @ CantorHCC in NYC! 🗓️ Sept 5 | 10:55 a.m. ET: Fireside chat w/ CEO Aoife Brennan, CMO Edgar Charles, and CBO Perrin Wilson Webcast: loom.ly/ytfUCfk Press release: loom.ly/qm7uF-wnews-ev… #CantorHCC

We’re hosting a webcast on CLYM116, our anti-APRIL antibody for IgAN, on Sept 29 at 8AM ET. Learn more about our approach: loom.ly/qm7uF-w #CLYM116 #IgAN #AutoimmuneResearch #ClimbBio #InvestorRelations

$CLYM continues its September investor lineup John Baird Global Healthcare Conference! 🗓️ Tuesday, Sept 9 🕓 4:20 p.m. ET | Fireside chat w/ CEO Aoife Brennan and CBO Perrin Wilson Webcast: loom.ly/qm7uF-w #BairdConference #HealthcareInnovation #IR

$CLYM will be at the Morgan Stanley Annual Global Healthcare Conference on Wed Sept 10. Our team looks forward to one-on-one investor meetings and connecting with leaders across the healthcare space. #ClimbBio #MorganStanleyHealthcare #InvestorRelations

Don’t miss our webcast happening on Sept 29 at 8AM ET! We’ll share new preclinical data on CLYM116 and its potential to evolve IgAN treatment. 🔗 More details here: loom.ly/34FrNk0 #CLYM116 #IgAN #ClimbBio #InvestorRelations

$CLYM is excited to join the Stifel Virtual Immunology & Inflammation Forum on Sept 16. 🕥 10:30 a.m. ET: Presentation from CEO Aoife Brennan on advancing therapeutics for immune-mediated diseases. Webcast: loom.ly/a90xDL4 #StifelForum #Immunology #InvestorRelations

Join $CLYM's webcast on 9/29 at 8AM ET to learn about CLYM116 program & the future of IgAN care. On deck: Aoife Brennan M.B., Ch.B.: CEO, $CLYM Edgar Charles, M.D., M.Sc.: CMO, $CLYM Craig Gordon, M.D., M.S.: Nephrologist, Tufts MC 🔗 loom.ly/a90xDL4

📢 Webcast: CLYM116 & the IgAN Opportunity 🗓️ Sept 29 | 8AM ET Hear from Climb Bio leaders + Dr. Craig Gordon on advancing therapies for IgA nephropathy. 🔗 loom.ly/a90xDL4 #CLYM116 #IgAN #ClimbBio

🚨 Happening soon! Join Climb Bio’s webcast on CLYM116 & IgAN today at 8AM ET. Learn about the current IgAN treatment landscape, unmet needs, and more: loom.ly/qm7uF-w #CLYM116 #IgAN

Please welcome Susan Altschuller, PhD, MBA as CFO at Climb Bio! She brings 20+ years of biopharma leadership, including CFO roles at Cerevel Therapeutics and ImmunoGen. Read more here: loom.ly/34FrNk0 $CLYM #CFO

Exciting news! Climb Bio’s abstract on CLYM116, our Fc-engineered anti-APRIL mAb for IgA nephropathy, has been accepted for #ASN2025. 📄Press Release: loom.ly/34FrNk0 ▶️ Webcast replay: loom.ly/1O-YdDc #CLYM116 #IgAN #Nephrology #ClimbBio #YearOfExecution